14 results about "Obstructive diseases" patented technology

Provided herein are novel DPP1 inhibitor compounds having the general structure of Formula (I), (II) or (III), or a pharmaceutically acceptable salt thereof. Also provided are certain methods of treatment, e.g., a method for treating an obstructive disease of the airway or a method of treating an inflammatory condition with a composition comprising an effective amount of one of the compounds provided herein.

The disclosure provides for methods and compositions for treating respiratory obstructive diseases.

The utility model relates to the technical field of medical equipment, in particular to a high-torsion-control soft-head ultra-smooth distance-measuring urinary mixed guide wire, an inner core of the guide wire is in a polygonal oval shape, the inner core of a soft head part is ground and processed into a polygonal oval gradually-changed slender inner core, and the farthest side end is in a flat polygonal oval slender shape. The top end is welded into a round ball head through plasma, a multilateral oval coil and a far-side multilateral oval coil are wound on an inner core of the guide wire soft head portion, the guide wire soft head portion and the guide-in section plastic-coated sleeve are made of polyurethane materials coated with hydrophilic coatings and consistent in color, the color of the guide wire soft head portion and the guide-in section plastic-coated sleeve is obviously different from that of the handheld operation section, and the handheld operation section plastic-coated sleeve is made of hydrophobic polytetrafluoroethylene. A positioning ranging ring or a ranging section is provided. According to the guide wire, the head flexibility, the tracking performance and the twisting control performance of the guide wire can be improved, the high lubricity of the soft head and the leading-in section is kept, it is guaranteed that the handheld operation section is easy to hold and operate, the guide wire can smoothly pass through a narrow obstructive diseased region, a user is accurately assisted in ranging under endoscope direct vision, and treatment is more accurate.

Provided is a nitrile derivative compound represented by formula (I), its stereoisomers, deuterated compounds, cocrystals, solvates or pharmaceutically acceptable salts, with each group as defined in the specification. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used for preparing drugs for treating diseases including airway obstructive diseases, bronchodilation, cystic fibrosis, asthma, emphysema and chronic obstructive pulmonary disease, etc.

Disclosed herein are novel DPP1 inhibitor compounds having the general structure of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof. Also provided are specific methods of treatment, such as a method for treating, for example, an obstructive disorder of the airway, or a method for treating an inflammatory condition, using a composition comprising an effective amount of one of the compounds provided herein.

The invention belongs to the field of pharmaceutics, particularly relates to a composition containing levosalbutamol hydrochloride and ipratropium bromide as well as a preparation method and application of the composition, and overcomes the defects of a stabilizer disodium ethylene diamine tetraacetate adopted in the prior art. The invention provides a levosalbutamol hydrochloride and ipratropium bromide composition which is simpler in prescription and better in safety, can be used for treating reversible bronchospasm related to airway obstructive diseases, can jointly act on muscarinic acid and beta2 adrenergic receptors in the lung, can enhance the bronchiectasia effect, takes effect quickly, and is free of toxic and side effects. The clinical application value is very high.

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

The invention discloses composite lipid nanoparticles as well as a preparation method and application thereof. The composite lipid nanoparticle comprises a lipid outer layer and an internal drug loading core, the lipid outer layer comprises lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-CREKA, and the internal drug loading core comprises fatty acid and a protein thrombolytic drug. The preparation method comprises the following steps: forming a lipid membrane, preparing a water-phase solution, hydrating the lipid membrane, extruding, filtering and the like. Thrombus targeting is achieved through a CREKA peptide mediated protein crown formation mechanism, the drug encapsulation efficiency is improved to 26.55% through fatty acid, and drug leakage is reduced. The composite lipid nanoparticles provided by the invention have good biocompatibility, can effectively dissolve thrombus and remarkably reduce the bleeding risk, and can be used for preparing medicines for treating thrombus obstructive diseases.

The present invention discloses a nitrile derivative compound represented by formula (I), its stereoisomers, deuterated compounds, co-crystals, solvates or pharmaceutically acceptable salts, and each group is as defined in the specification. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used for preparing drugs for treating diseases including airway obstructive diseases, bronchiectasis, cystic fibrosis, asthma, emphysema and chronic obstructive pulmonary disease, etc.

The invention relates to the technical field of medical image processing and computer-aided diagnosis, and discloses a nasolacrimal duct obstructive disease CT image-aided diagnosis model construction method, which comprises the following steps of: firstly, performing three-dimensional reconstruction and standardized preprocessing on orbit CT data; constructing a first-stage global diagnosis model, positioning the focus center of gravity and outputting a cause classification result; intercepting a local region-of-interest tensor by using the barycentric coordinates, and constructing a second-level fine diagnosis model based on semi-supervised learning; training the second-level model through the joint of supervised learning of the labeled data and the consistency constraint task of the unlabeled data, and outputting a smoothness grading result; and finally, an auxiliary diagnosis report and a visual image are generated in combination with the cause of disease and the patency result. According to the method, a coarse-to-fine cascade architecture and a semi-supervised strategy are adopted, so that the dependence on labeled data is reduced, and the diagnosis precision and clinical interpretability of the nasolacrimal duct microstructure are effectively improved.

The present invention relates to salts of budesonide 21-phosphate with a beta2 adrenaline agonist, and preferably with formoterol, pharmaceutical compositions comprising the same and their use in the treatment of respiratory tract inflammatory diseases, obstructive diseases and allergen-induced airway dysfunction. The invention also relates to a method for preparing said salt.

The invention relates to the technical field of medical image processing, and discloses a multi-modal image fusion nasolacrimal duct obstructive disease diagnosis and grading system which comprises the following steps: acquiring head CT data, performing space standardization, and generating osseous channel and soft tissue channel input tensors based on double-window parameters; a double-flow attention interaction network is constructed, a spatial attention mask is generated by using a bony feature extraction branch, and weighted fusion is performed on the pathological features of the soft tissue through a topology guide attention unit; a semi-supervised model training module is adopted, a consistency constraint strategy is executed on unlabeled samples, and network parameters are updated by minimizing a composite loss function; and finally outputting disease property classification and blocking degree grading results. According to the method, the bony anatomical structure and the soft tissue pathological information can be effectively combined, the model performance is improved by using the unlabeled data, and high-precision automatic diagnosis and grading of nasolacrimal duct blockage are realized.

The present application relates to a kind of based on 5G slice and UWB slow obstructive disease rehabilitation training monitoring system, specifically relates to the field of slow obstructive disease rehabilitation, by real-time analysis user training posture and respiratory waveform, accurately determine rehabilitation stage and data key, and fusion network state, drive reinforcement learning model intelligent generation collaborative resource scheduling strategy for 5G core network and home gateway, to provide end-to-end service quality guarantee in multiple concurrent scenarios for high-value medical data stream through wireless access to core network, closed-loop optimization mechanism based on real transmission effect, so that resource allocation strategy can continuously self-improve, finally realize reliable, accurate remote rehabilitation monitoring, and improve network resource utilization efficiency.

The present disclosure provides methods of treating an individual for a muco-obstructive, the methods including: administering to the individual a b-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.